A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer Journal Article


Authors: Segal, N. H.; Gada, P.; Senzer, N.; Gargano, M. A.; Patchen, M. L.; Saltz, L. B.
Article Title: A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer
Abstract: Micro-Abstract Cetuximab alone is ineffective in KRAS-mutant colorectal cancer. Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose), a yeast-derived beta-glucan polymer, activates innate immune effector cells enabling recognition and killing of tumor coated by a complement-activating antibody, such as cetuximab. In this phase II study, immune therapy for KRAS-mutant colorectal cancer with Imprime PGG plus cetuximab was assessed. The combination was safe and compelling, albeit modest, clinical activity was shown. © 2016 Elsevier Inc.
Keywords: epidermal growth factor receptor; antibody; complement; immune; β-glucan
Journal Title: Clinical Colorectal Cancer
Volume: 15
Issue: 3
ISSN: 1533-0028
Publisher: Elsevier Inc.  
Date Published: 2016-09-01
Start Page: 222
End Page: 227
Language: English
DOI: 10.1016/j.clcc.2016.02.013
PROVIDER: scopus
PUBMED: 26975418
PMCID: PMC5621519
DOI/URL:
Notes: Article -- Export Date: 6 December 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Leonard B Saltz
    599 Saltz
  2. Neil Howard Segal
    107 Segal